Table 2.
95% confidence intervals for quantitative immunoblot analysis of mTOR pathway components
| TSG cohot 1 | TSG cohort 3 | ||||
|---|---|---|---|---|---|
| Protein | Arm | 95% Confidence interval | Protein | Arm | 95% Confidence interval |
| p-4.FRP1 | Placebo | (1.46, 1.97) | Placebo | (0.87, 1.08) | |
| MLN0128 | (2.13, 2.58) | P-4EBP1 | Temsirolimus | (0.81, 0.95) | |
| HIF1-alpha | Placebo | (1.48, 1.81) | MLN0128 | (1.69, 2.22) | |
| MLN0128 | (1.83, 2.21) | Placebo | (1.19, 1.54) | ||
| MTA1 | Placebo | (1.72, 1.95) | HIF1-alpha | Temsirolimus | (1.34, 1.54) |
| MLN0128 | (2.02, 2.44) | MLN0128 | (1.55, 1.88) | ||
| c-MYC | Placebo | (0.96, 1.21) | Placebo | (0.71, 1.03) | |
| MLN0128 | (1.30, 1.51) | P-S6K1 | Temsirolimus | (0.68, 0.93) | |
| MLN0128 | (1.08, 1.23) | ||||
| Placebo | (1.17, 1.71) | ||||
| p-AKT | Temsirolimus | (0.84, 1.12) | |||
| MLN0128 | (1.05, 1.36) | ||||